Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistimethate Sodium vs Coly-Mycin M in Carbapenem-Resistant Gram-Negative Infections
NCT06198764Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of colistimethate sodium in Gram-negative bacterial infection, hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2023; status: recruiting.
02
Drugs
colistimethate sodium
03
Conditions
Gram-negative bacterial infectionhospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT06198764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198764.